[Form 4] BIO-TECHNE Corp Insider Trading Activity

Rhea-AI Filing Summary

Bio-Techne (TECH) director John L. Higgins filed a Form 4 reporting equity awards dated 10/30/2025. He acquired 1,640 shares of common stock at $0, bringing his directly held common stock to 66,876 shares after the transaction. He was also granted stock options for 3,777 shares with an exercise price of $60.96, expiring on 10/30/2035. The options vest on the earlier of the one‑year anniversary of the grant date or Bio‑Techne’s 2026 annual meeting of shareholders.

Insider Trade Summary

11 transactions reported

Mixed 11 txns

Insider HIGGINS JOHN L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	3,777	$0.00	--
Grant/Award	Common Stock	1,640	$0.00	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 3,777 shares (Direct); Common Stock — 66,876 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HIGGINS JOHN L

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		A		1,640	A	$0	66,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$25.3							10/26/2017	10/26/2026	Common Stock	15,940		15,940	D
Stock Options (Right to Buy)	$31.26							10/25/2018	10/26/2027	Common Stock	12,500		12,500	D
Stock Options (Right to Buy)	$44.96							10/24/2019	10/25/2028	Common Stock	7,592		7,592	D
Stock Options (Right to Buy)	$50.41							10/24/2020	10/24/2029	Common Stock	8,044		8,044	D
Stock Options (Right to Buy)	$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D
Stock Options (Right to Buy)	$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D
Stock Options (Right to Buy)	$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D
Stock Options (Right to Buy)	$61.51							10/24/2024	10/26/2033	Common Stock	3,937		3,937	D
Stock Options (Right to Buy)	$68.37							10/24/2025	10/24/2034	Common Stock	3,511		3,511	D
Stock Options (Right to Buy)	$60.96	10/30/2025		A		3,777		(1)	10/30/2035	Common Stock	3,777	$0	3,777	D

Explanation of Responses:

1. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

	/s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bio‑Techne (TECH) disclose in this Form 4?

Director John L. Higgins reported acquiring 1,640 common shares at $0 and receiving options for 3,777 shares at an exercise price of $60.96 on 10/30/2025.

How many Bio‑Techne (TECH) shares does the director own after the transaction?

Following the reported transaction, he directly owns 66,876 common shares.

What are the terms of the new stock options reported by TECH?

The options cover 3,777 shares, have a $60.96 exercise price, and expire on 10/30/2035.

When do the new Bio‑Techne (TECH) options vest?

They vest on the earlier of the one‑year anniversary of the grant date or the company’s 2026 annual meeting.

Was cash paid for the 1,640 Bio‑Techne (TECH) shares?

The filing lists the acquisition price as $0 for the 1,640 common shares.

Is the ownership reported as direct or indirect for TECH?

Both the common stock and the new option grant are reported as Direct (D) ownership.